Artificial intelligence is beginning to transform the way scientists discover and develop new medicines. Researchers and pharmaceutical companies are now using AI tools to analyse large amounts of biological data and identify potential drug compounds much faster than traditional methods.
Developing a new drug has traditionally been a long and expensive process, often taking more than a decade and costing billions of dollars. Scientists must test thousands of chemical compounds before finding one that works safely in the human body. AI is helping shorten this early research stage by quickly analysing huge chemical databases and predicting which molecules could be effective against specific diseases.
New AI systems can study millions of chemical structures and protein targets in a short time, something that would take years using conventional laboratory screening. By identifying the most promising compounds early, researchers can focus their experiments on the best candidates and avoid unnecessary testing.
In some laboratories, AI is also being combined with robotics to create automated research environments. These “self-driving labs” can run experiments, study the results and plan the next set of tests without constant human intervention. This allows scientists to test more ideas quickly and explore complex chemical combinations that might otherwise be overlooked.
AI will not replace scientists but will act as a powerful tool to support their work. By handling massive datasets and complex calculations, AI allows researchers to focus more on designing experiments and understanding results.
Large pharmaceutical companies and biotechnology firms are investing heavily in AI technology to improve their research pipelines. The technology is being used not only to design new drug molecules but also to help identify disease targets and analyse clinical trial data.
Also Read: Jagsonpal Pharmaceuticals shares rise, board considers buyback
